Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Monopar Therapeutics has joined Rosalind Franklin University's Helix 51 biomedical incubator community. The clinical-stage biotech company is developing personalized radiopharmaceuticals for cancer diagnosis and treatment, along with a late-stage drug for Wilson Disease.
The company will utilize Helix 51's labs and resources to advance its research objectives. Radiopharmaceuticals, which selectively target cancer cells with radioisotopes, are important in nuclear medicine, enabling precise diagnosis and treatment while minimizing damage to healthy tissues.
Helix 51 is Lake County, Illinois' only wet-and dry-lab based incubator, situated in a region hosting over 122 bioscience companies and 33,000 bioscience jobs. The facility is part of RFU's Innovation and Research Park, which offers research space and core facilities for drug, device, and diagnostic R&D.
Monopar Therapeutics si è unita alla comunità dell'incubatore biomedicale Helix 51 della Rosalind Franklin University. L'azienda biotecnologica in fase clinica sta sviluppando radiofarmaci personalizzati per la diagnosi e il trattamento del cancro, insieme a un farmaco in fase avanzata per la Malattia di Wilson.
L'azienda utilizzerà i laboratori e le risorse di Helix 51 per progredire nei suoi obiettivi di ricerca. I radiofarmaci, che mirano selettivamente alle cellule tumorali con radioisotopi, sono importanti nella medicina nucleare, consentendo diagnosi e trattamenti precisi minimizzando i danni ai tessuti sani.
Helix 51 è l'unico incubatore basato su laboratori umidi e secchi nella Contea di Lake, Illinois, situato in una regione con oltre 122 aziende nel settore delle bioscienze e 33.000 posti di lavoro nel campo bioscientifico. La struttura fa parte del Parco dell'Innovazione e della Ricerca della RFU, che offre spazi di ricerca e strutture di base per la R&D di farmaci, dispositivi e diagnostica.
Monopar Therapeutics se ha unido a la comunidad del incubador biomédico Helix 51 de la Universidad Rosalind Franklin. La empresa biotecnológica en fase clínica está desarrollando radiofármacos personalizados para el diagnóstico y tratamiento del cáncer, junto con un medicamento en fase avanzada para la Enfermedad de Wilson.
La empresa utilizará los laboratorios y recursos de Helix 51 para avanzar en sus objetivos de investigación. Los radiofármacos, que apuntan selectivamente a las células cancerosas con radioisótopos, son importantes en la medicina nuclear, permitiendo diagnósticos y tratamientos precisos mientras minimizan el daño a los tejidos sanos.
Helix 51 es el único incubador en el Condado de Lake, Illinois, basado en laboratorios húmedos y secos, situado en una región que alberga más de 122 empresas de biosciencia y 33,000 empleos en el ámbito bioscienífico. La instalación forma parte del Parque de Innovación e Investigación de RFU, que ofrece espacio de investigación e instalaciones básicas para I+D de medicamentos, dispositivos y diagnósticos.
Monopar Therapeutics가 Rosalind Franklin University의 Helix 51 생의학 인큐베이터 커뮤니티에 가입했습니다. 이 임상 단계의 생명공학 회사는 암 진단 및 치료를 위한 맞춤형 방사성 의약품과 Wilson병에 대한 후기 단계 약물을 개발하고 있습니다.
회사는 Helix 51의 실험실과 자원을 이용하여 연구 목표를 발전시킬 것입니다. 방사성 의약품은 방사성 동위원소를 이용해 선택적으로 암세포를 타겟팅하며, 핵의학에서 중요한 역할을 하여 건강한 조직에 대한 손상을 최소화하면서 정밀한 진단과 치료를 가능하게 합니다.
Helix 51은 일리노이주 레이크 카운티의 유일한 습식 및 건식 실험실 기반 인큐베이터로, 122개 이상의 생명과학 회사와 33,000개의 생명과학 직업이 있는 지역에 위치해 있습니다. 이 시설은 RFU의 혁신 및 연구 공원의 일환으로, 의약품, 기기 및 진단 연구 개발을 위한 연구 공간 및 핵심 시설을 제공합니다.
Monopar Therapeutics a rejoint la communauté de l'incubateur biomédical Helix 51 de l'Université Rosalind Franklin. Cette entreprise biopharmaceutique en phase clinique développe des radio-pharmaceutiques personnalisés pour le diagnostic et le traitement du cancer, ainsi qu'un médicament en phase avancée pour la maladie de Wilson.
L'entreprise utilisera les laboratoires et les ressources de Helix 51 pour faire progresser ses objectifs de recherche. Les radio-pharmaceutiques, qui ciblent sélectivement les cellules cancéreuses avec des radio-isotopes, sont importants en médecine nucléaire, permettant des diagnostics et des traitements précis tout en minimisant les dommages aux tissus sains.
Helix 51 est le seul incubateur basé sur des laboratoires humides et secs dans le comté de Lake, dans l'Illinois, situé dans une région abritant plus de 122 entreprises de biotechnologie et 33 000 emplois dans le domaine des biosciences. L'établissement fait partie du parc d'innovation et de recherche de RFU, qui offre des espaces de recherche et des installations essentielles pour la R&D de médicaments, de dispositifs et de diagnostics.
Monopar Therapeutics ist der Gemeinschaft des biomedizinischen Inkubators Helix 51 der Rosalind Franklin University beigetreten. Das biopharmazeutische Unternehmen in der klinischen Phase entwickelt personalisierte Radiopharmazeutika für die Diagnose und Behandlung von Krebs sowie ein Medikament in der späten Phase für die Wilson-Krankheit.
Das Unternehmen wird die Labore und Ressourcen von Helix 51 nutzen, um seine Forschungsziele voranzutreiben. Radiopharmazeutika, die gezielt Krebszellen mit radioaktiven Isotopen anvisieren, sind in der Nuklearmedizin wichtig, da sie präzise Diagnosen und Behandlungen ermöglichen und gleichzeitig Schäden an gesundem Gewebe minimieren.
Helix 51 ist das einzige Inkubator in Lake County, Illinois, das über nasse und trockene Labore verfügt, und befindet sich in einer Region mit über 122 Biowissenschaftsunternehmen und 33.000 Biowissenschaftsjobs. Die Einrichtung ist Teil des Innovations- und Forschungsparks der RFU, der Forschungsräume und Kernanlagen für die F&E von Arzneimitteln, Geräten und Diagnostika bietet.
- Access to advanced research facilities and resources through Helix 51 incubator
- Strategic location in major bioscience hub with 122+ companies
- Additional research support available from RFU's specialized research centers
- None.
Insights
This strategic move positions Monopar Therapeutics to accelerate its development pipeline through multiple synergistic advantages. The Helix 51 incubator provides important wet-lab infrastructure and specialized equipment that typically requires significant capital investment, allowing Monopar to allocate resources more efficiently toward actual research and development.
The location within Lake County's biotech cluster, home to 122 bioscience companies and 33,000 bioscience jobs, offers compelling advantages: access to specialized talent, potential research collaborations and proximity to major pharmaceutical companies. The radiopharmaceutical market is experiencing rapid growth, with recent research highlighting improved efficiency in tumor diagnosis and therapy. This field's expansion is driven by increasing demand for targeted cancer treatments that minimize collateral damage to healthy tissue.
Particularly noteworthy is the access to RFU's research centers, specifically the Center for Cancer Cell Biology, Immunology and Infection and the Center for Genetic Diseases. These resources could significantly expedite both:
- The development of their radiopharmaceutical pipeline for advanced solid tumors
- The progression of ALXN1840 for Wilson Disease
The collaborative environment at Helix 51, combined with the comprehensive research support infrastructure, positions Monopar to potentially accelerate their development timelines while reducing operational costs. This strategic decision could enhance their competitive position in the rapidly evolving radiopharmaceutical space and rare disease markets.
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease
Monopar, a clinical-stage biotechnology firm, is developing personalized and precise radiopharmaceuticals to diagnose and treat aggressive cancers, and will utilize the labs and other resources in Helix 51 to further its research objectives.
"We are excited to be a part of the vibrant biomedical community at RFU," said Monopar COO Andrew Cittadine, MBA. "We see this as an opportunity to accelerate the development of new products and were drawn to the talented and collaborative community at Helix 51."
Radiopharmaceuticals — drugs that selectively target cancer and are linked with radioisotopes — are a key component of nuclear medicine. Rapid advancements in the field have significantly improved healthcare by enabling highly targeted diagnosis and treatment of diseases, particularly cancer, through the precise delivery of radiation directly to diseased tissues. The technique helps minimize damage to healthy organs, leading to earlier detection, more effective therapies and improved patient outcomes with fewer side effects.
An article published this month in the journal Signal Transduction and Targeted Therapy hailed the technology's ability to "improve the efficiency and biosafety of tumour diagnosis and therapy."
Monopar is also working on a late-stage investigational drug for the treatment of Wilson Disease, a rare genetic disorder.
Helix 51 is the only wet-and dry-lab based incubator in
"Rosalind Franklin University is committed to expanding collaboration between academic research and the life-science industry to develop new therapeutic solutions for difficult-to-treat diseases," said Dr. Joseph DiMario, RFU interim vice president for research. "Our Center for Cancer Cell Biology, Immunology, and Infection and Center for Genetic Diseases can also provide additional research support and expertise to Monopar. We're pleased to include them in our growing oncology cluster of companies."
About Rosalind Franklin University
Rosalind Franklin University of Medicine and Science is committed to serving humanity through the interprofessional education of health and biomedical professionals and the discovery of knowledge dedicated to improving wellness. The university embodies the spirit of inquiry and excellence modeled by its namesake Dr. Rosalind Franklin, whose Photo 51 was crucial to solving the structure of DNA. Recognized for its research in areas including neuroscience, brain-related diseases, inherited disorders, diabetes, obesity, and gait and balance, RFU encompasses the Chicago Medical School, College of Health Professions, College of Nursing, College of Pharmacy, School of Graduate and Postdoctoral Studies and the Dr. William M. Scholl College of Podiatric Medicine. Learn more at rosalindfranklin.edu.
Office of Marketing and Communications
media@rosalindfranklin.edu
View original content to download multimedia:https://www.prnewswire.com/news-releases/rosalind-franklin-universitys-helix-51-incubator-welcomes-monopar-therapeutics-302358955.html
SOURCE Rosalind Franklin University of Medicine and Science
FAQ
What is Monopar Therapeutics (MNPR) developing at Helix 51 incubator?
How will joining Helix 51 benefit MNPR's research and development?
What are the key focus areas of MNPR's radiopharmaceutical research?
What additional resources will be available to MNPR at Rosalind Franklin University?
